Edition:
India

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

5.93CAD
1:30am IST
Change (% chg)

$0.24 (+4.22%)
Prev Close
$5.69
Open
$5.49
Day's High
$5.99
Day's Low
$5.49
Volume
93,900
Avg. Vol
98,156
52-wk High
$9.88
52-wk Low
$4.86

Latest Key Developments (Source: Significant Developments)

Theratechnologies Announces Financial Results For Q2 2019
Thursday, 11 Jul 2019 

July 11 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2019.THERATECHNOLOGIES INC - QTRLY LOSS PER SHARE $0.04.THERATECHNOLOGIES INC - Q2 NET SALES OF $15.6 MILLION, UP 62.6% FROM SAME QUARTER LAST YEAR.THERATECHNOLOGIES INC - CONFIRMED THAT BOARD AUTHORIZED MANAGEMENT TO APPLY FOR LISTING OF COMMON SHARES ON NASDAQ.THERATECHNOLOGIES - AS AT MAY 31, CASH & BONDS AMOUNTED TO ABOUT $43.1 MILLION VERSUS ABOUT $53.9 MILLION AT NOV 30, 2018.THERATECHNOLOGIES - SHORTLY, EXPECT A RECOMMENDATION FROM CHMP FOR TROGARZO IN EUROPE AND LAUNCH OF NEW EGRIFTA SV IN UNITED STATES.  Full Article

Theratechnologies Posts Q2 Net Sales Of $15.6 Million
Thursday, 11 Jul 2019 

July 11 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2019.THERATECHNOLOGIES INC - Q2 NET SALES OF $15.6 MILLION, UP 62.6% FROM SAME QUARTER LAST YEAR.THERATECHNOLOGIES INC - CONFIRMED THAT BOARD AUTHORIZED MANAGEMENT TO APPLY FOR LISTING OF COMMON SHARES ON NASDAQ.THERATECHNOLOGIES INC QTRLY LOSS PER SHARE $0.04.THERATECHNOLOGIES INC - EXPECT A RECOMMENDATION FROM CHMP FOR TROGARZO IN EUROPE AND LAUNCH OF NEW EGRIFTA SV IN UNITED STATES.THERATECHNOLOGIES INC - AS AT MAY 31, 2019, CASH AND BONDS AMOUNTED TO ABOUT $43 MILLION COMPARED TO ABOUT $53.8 MILLION AT NOVEMBER 30, 2018.  Full Article

Theratechnologies Announces Financial Results For The First Quarter Of 2019
Thursday, 4 Apr 2019 

April 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2019.Q1 NET SALES OF $15.2 MILLION, UP 86%.Q1 LOSS PER SHARE $0.02.QTRLY LOSS PER SHARE $0.02.  Full Article

Theratechnologies Says FDA Approves Novel Single-Vial Formulation Of Egrifta
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Theratechnologies Inc ::FDA APPROVES NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA®.THERATECHNOLOGIES INC - FDA APPROVES EGRIFTA FOR TREATMENT OF EXCESS ABDOMINAL VISCERAL ADIPOSE TISSUE IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY.  Full Article

European Medicines Agency Validates Marketing Authorization Application For Trogarzo
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Theratechnologies Inc ::EUROPEAN MEDICINES AGENCY VALIDATES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO.EMA WILL REVIEW APPLICATION FOR TROGARZO UNDER ACCELERATED ASSESSMENT PROCEDURE.SEEKS TO OBTAIN APPROVAL FOR TROGARZO FOR TREATMENT OF MULTIDRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS-1 IN EUROPEAN UNION.RELATED TO EMA CONFIRMING VALIDITY OF MARKETING AUTHORIZATION APPLICATION FOR TROGARZO, START OF PROCEDURE DATE BEEN SET TO SEPT 13.  Full Article

Theratechnologies Files Marketing Authorization Application For Trogarzo
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES FILES MARKETING AUTHORIZATION APPLICATION FOR TROGARZO IN EUROPE.THERATECHNOLOGIES INC - EMA HAS UNTIL MID-SEPTEMBER TO CONFIRM WHETHER APPLICATION IS COMPLETE.  Full Article

Theratechnologies Reports Q4 Loss Per Share Of C$0.06
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017.Q4 REVENUE C$12.6 MILLION VERSUS C$10.38 MILLION.Q4 LOSS PER SHARE C$0.06.  Full Article

Theratechnologies Q3 loss per share c$0.04
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - Theratechnologies Inc ::Theratechnologies announces financial results for third quarter of 2017.Q3 loss per share c$0.04.Q3 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies - ‍net sales revenue of Egrifta for fiscal 2017 is now expected to be in range of $42 million to $44 million​.  Full Article